Respiratory diseases are a significant challenge to treat, but inhalable medicines offer a promising solution. The key to success lies in delivering tiny aerosol particles to the correct location in the lungs at the right dosage. However, this process can be complex, as factors such as the type of drug, delivery method, and individual patient characteristics can affect the effectiveness of the treatment.
University of Delaware Assistant Professor Catherine Fromen, along with current graduate student Dominic Hoffman and two UD alumni, have developed an innovative 3D lung model. This model can replicate realistic breathing patterns and provide personalized evaluation of aerosol therapeutics under various breathing conditions. By testing the effectiveness of inhalable medications in this model, the researchers aim to improve the delivery and efficacy of these treatments.
In a recent publication in the journal Device, Fromen and her team showcase how their 3D lung model can enhance our understanding of how inhalable medications behave in different regions of the lung. This research paves the way for predicting the effectiveness of inhalable medications in diverse populations and age groups, offering valuable insights for personalized medicine.
The structure of the lung is intricate, resembling a branching tree that culminates in delicate alveoli where gas exchange occurs. Mimicking this complexity in a lab setting is challenging, but the UD-developed 3D lung model stands out for its unique features. The model replicates the cyclic motion of real lungs and incorporates lattice structures to mimic the lung’s volume and surface area. This innovative design allows researchers to study the deposition and distribution of inhaled medications with precision.
The testing process involves exposing the 3D lung model to aerosols and tracking the deposition of particles in different regions of the model. By analyzing the data, researchers can create heat maps to visualize how aerosols travel through the lung model’s airways. This information can be compared to clinical data to validate the model’s accuracy and effectiveness.
The versatility of the 3D lung model enables researchers to simulate various breathing conditions, such as asthma attacks or COPD, to study how these factors impact aerosol deposition. By understanding how aerosols behave in different scenarios, researchers can tailor inhalable medications to individual patient needs, potentially leading to more effective treatments.
Apart from pharmaceutical development, the UD-developed lung model also has applications in toxicology research. By studying environmental exposures and the impact of toxins on lung health, researchers can gain valuable insights into respiratory health and disease prevention.
Overall, the innovative 3D lung model developed by the University of Delaware offers a valuable tool for advancing research in respiratory medicine and personalized healthcare. By sharing their design and methods with the scientific community, Fromen and her team hope to foster collaborations and optimize treatments for specific respiratory conditions.
